Zenas BioPharma, Inc.
ZBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $10,000 | $5,000 |
| % Growth | – | -100% | 100% | – |
| Cost of Goods Sold | $5,000 | $43,027 | $0 | $0 |
| Gross Profit | -$5,000 | -$43,027 | $10,000 | $5,000 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $34,402 | $43,027 | $34,915 | $49,157 |
| G&A Expenses | $13,178 | $11,333 | $12,415 | $11,466 |
| SG&A Expenses | $13,178 | $12,136 | $12,415 | $11,466 |
| Sales & Mktg Exp. | $0 | $803 | $0 | $0 |
| Other Operating Expenses | $0 | -$43,027 | $0 | $0 |
| Operating Expenses | $47,580 | $12,136 | $47,330 | $60,623 |
| Operating Income | -$52,580 | -$55,163 | -$37,330 | -$55,623 |
| % Margin | – | – | -373.3% | -1,112.5% |
| Other Income/Exp. Net | $1,081 | $2,960 | $3,552 | $3,448 |
| Pre-Tax Income | -$51,499 | -$52,203 | -$33,778 | -$52,175 |
| Tax Expense | $0 | $20 | -$205 | $429 |
| Net Income | -$51,499 | -$52,223 | -$33,573 | -$52,604 |
| % Margin | – | – | -335.7% | -1,052.1% |
| EPS | -1.22 | -1.25 | -0.8 | -1.26 |
| % Growth | 2.4% | -56.2% | 36.5% | – |
| EPS Diluted | -1.22 | -1.25 | -0.8 | -1.26 |
| Weighted Avg Shares Out | 42,159 | 41,865 | 41,801 | 41,790 |
| Weighted Avg Shares Out Dil | 42,159 | 41,865 | 41,801 | 41,790 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $11 | $12 | $23 | $33 |
| EBITDA | -$51,488 | -$55,151 | -$33,755 | -$55,590 |
| % Margin | – | – | -337.6% | -1,111.8% |